India’s Zydus Has Expansion Plans In Japan After Nippon Acquisition
This article was originally published in PharmAsia News
Zydus Cadila, an Indian pharmaceutical company, plans to release its first new generic drug in 10 years and expand its portfolio of other generics in Japan. Zydus acquired the Japanese generics maker, Nippon Universal Pharmaceutical, last April. The new drug launched by Zydus is a generic of UCB Japan's Zyrtec (cetirizine hydrochloride) for treating allergies. The Nippon arm plans to acquire the sales rights for nine other generics drugs to add to its portfolio of six, and increase its sales representative staff from 11 to 25 by next October. (Click here for more - may require a subscription
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.